Keyphrases
Canada
100%
Congestive Heart Failure
100%
Pharmacological Treatment
100%
Nova Scotia
42%
Prescription Rate
28%
Hospital Discharge
28%
British Columbia
28%
Quebec
28%
Alberta
28%
Patient Management
14%
Consecutive Patients
14%
Developed Countries
14%
Observation Period
14%
Morbidity Mortality
14%
Hospital Records
14%
Beta-blockers
14%
Use Rate
14%
Cardiovascular Outcomes
14%
Evidence-based Treatment
14%
Angiotensin-converting Enzyme Inhibitor (ACEi)
14%
Pharmacological Management
14%
Use of Evidence
14%
Angiotensin Receptor Blockers
14%
Digoxin
14%
Disease-specific
14%
Resource Consumption
14%
Health Resources
14%
Principal Diagnosis
14%
Drug Benefit Plans
14%
Discharge Medication
14%
Spironolactone
14%
Minimal Change
14%
Heart Failure Management
14%
Administrative Data Sources
14%
Neuroscience
Angiotensin Receptor
100%
ACE Inhibitor
100%
Digoxin
100%
Beta Blocker
100%
Spironolactone
100%
Nursing and Health Professions
Drug Therapy
100%
Congestive Heart Failure
100%
Hospital Discharge
28%
Disease
14%
Health Care Planning
14%
Angiotensin Receptor Antagonist
14%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Medical Record
14%
Digoxin
14%
Beta Adrenergic Receptor Blocking Agent
14%
Spironolactone
14%
Medicine and Dentistry
Drug Therapy
100%
Congestive Heart Failure
100%
Disease
14%
Gene Linkage
14%
Cardiovascular System
14%
ACE Inhibitor
14%
Angiotensin Receptor Antagonist
14%
Digoxin
14%
Spironolactone
14%
Beta Adrenergic Receptor Blocking Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Congestive Heart Failure
100%
Agrotis
42%
Disease
14%
Dipeptidyl Carboxypeptidase Inhibitor
14%
Angiotensin Receptor Antagonist
14%
Digoxin
14%
Beta Adrenergic Receptor Blocking Agent
14%
Spironolactone
14%